Ramsay Stattman Vela & Price Inc. Acquires 1,582 Shares of Waters Corporation $WAT

Ramsay Stattman Vela & Price Inc. bought a new position in shares of Waters Corporation (NYSE:WAT – Free Report) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 1,582 shares of the medical instruments supplier’s stock, valued at approximately $695,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. PenderFund Capital Management Ltd. bought a new stake in shares of Waters in the second quarter worth about $28,000. First Bancorp Inc ME bought a new stake in Waters in the 2nd quarter valued at approximately $30,000. Caitlin John LLC boosted its holdings in Waters by 43.9% during the second quarter. Caitlin John LLC now owns 82 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 25 shares during the last quarter. SHP Wealth Management acquired a new position in shares of Waters during the 4th quarter worth about $32,000. Finally, Anchor Investment Management LLC bought a new position in shares of Waters in the 1st quarter valued at about $27,000. 94.01% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

WAT has been the topic of a number of recent research reports. Wall Street Zen downgraded Waters from a “buy” rating to a “hold” rating in a research report on Sunday. Citigroup increased their price target on Waters from $425.00 to $470.00 and gave the company a “buy” rating in a research report on Monday, August 10th. Barclays raised their price target on Waters from $460.00 to $500.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $400.00 price target on shares of Waters in a research report on Wednesday, August 5th. Finally, UBS Group upgraded Waters from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $375.00 to $490.00 in a research note on Wednesday, September 9th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $443.79.

Check Out Our Latest Report on WAT

Waters Price Performance

NYSE:WAT opened at $434.99 on Tuesday. Waters Corporation has a one year low of $282.77 and a one year high of $454.54. The company has a market cap of $42.74 billion, a P/E ratio of 108.48, a P/E/G ratio of 2.54 and a beta of 1.15. The firm’s fifty day moving average price is $421.29 and its two-hundred day moving average price is $377.73. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.86 and a quick ratio of 1.29.

Waters (NYSE:WAT – Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The medical instruments supplier reported $3.05 earnings per share for the quarter, beating the consensus estimate of $3.01 by $0.04. The firm had revenue of $1.65 billion for the quarter, compared to analysts’ expectations of $1.62 billion. Waters had a net margin of 3.58% and a return on equity of 11.27%. The business’s revenue was up 113.3% on a year-over-year basis. During the same period in the prior year, the firm earned $2.95 EPS. Waters has set its Q3 2026 guidance at 3.950-4.050 EPS and its FY 2026 guidance at 14.450-14.650 EPS. Equities analysts expect that Waters Corporation will post 14.56 earnings per share for the current year.

Insider Activity at Waters

In other news, Director Christopher Kuebler sold 3,626 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $397.94, for a total value of $1,442,930.44. Following the transaction, the director owned 17,808 shares of the company’s stock, valued at approximately $7,086,515.52. This represents a 16.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.31% of the company’s stock.

About Waters

(Free Report)

Waters Corporation (NYSE:WAT) develops and manufactures analytical technologies used to measure, identify and characterize chemical and biological substances. Its customers include pharmaceutical and biotechnology companies, industrial manufacturers, academic and government laboratories, and organizations involved in food, environmental and clinical testing.

The company’s product portfolio includes high-performance liquid chromatography and ultra-performance liquid chromatography systems, mass spectrometers, chromatography columns and consumables, and laboratory software for data management and analysis.

Featured Articles

• Five stocks we like better than Waters
• Tesla’s Roadster Reveal Hints at 2 Much Bigger Moves
• The AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance Anyway
• Mr. Wonderful’s Test for AI Data Center Stocks: Power, Permits, and Tenants
• Alcoa Beat Earnings, But Can It Escape the Aluminum Bears?

Want to see what other hedge funds are holding WAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Waters Corporation (NYSE:WAT – Free Report).